Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Pulmatrix, Inc. (PULM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.6200-0.0100 (-0.22%)
At close: 04:00PM EDT
4.8300 +0.20 (+4.32%)
After hours: 05:38PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close4.6300
Open4.6800
Bid4.6000 x 1200
Ask4.9100 x 1400
Day's Range4.6200 - 4.7700
52 Week Range4.0320 - 20.8000
Volume9,679
Avg. Volume62,261
Market Cap15.649M
Beta (5Y Monthly)1.07
PE Ratio (TTM)N/A
EPS (TTM)-8.1950
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for PULM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Pulmatrix, Inc.
    Mid Cap U.S. Pick List August 2022This pick list highlights constituents of the Morningstar US Mid Cap Index that we believe offer investors the best risk-adjusted return prospects. The market capitalization range for U.S. mid-caps typically falls between $1 billion and $8 billion and represents 20% of the total capitalization of the U.S. equity market.
    Rating
    Fair Value
    Economic Moat
    9 days agoMorningstar
View more
  • PR Newswire

    Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

    Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced second quarter financial results for 2022 and provided a corporate update related to its development programs.

  • PR Newswire

    Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

    Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced the dosing of the first five subjects in a Phase 1 trial evaluating PUR3100, a novel pulmonary inhaled formulation of dihydroergotamine (DHE). PUR3100 is formulated using Pulmatrix's iSPERSE drug delivery technology and is being developed for the treatment of acute migraine.

  • PR Newswire

    Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update

    Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced first quarter financial results for 2022 and provided a corporate update.

Advertisement
Advertisement